Global Surgeon Experience Demonstrates AxioMed Freedom® Viscoelastic Disc Will Be Revolutionary

AxioMed clinical experience across continents continues to point to the benefits of the AxioMed disc replacement, as Professor Dr. Kingsley R. Chin shares his clinical assessment, stating, “I was pleased with the motion seen between the spinous processes and facets immediately after implanting the AxioMed viscoelastic cervical disc during a recent case in Kingston, Jamaica. I noted that the disc needs some time to warm to body temperature to see more compression of the disc. In this case we inspected the motion immediately after implantation while the wound was still open.”

President of AxioMed Jake Lubinski added, “Dr. Chin’s experience is being echoed by surgeons, many implanting the disc for the first time, who can’t believe how simple and natural the sizing and placement of the disc is.”

Dr. Chin emphasized how easy the surgery is, pointing out, “Surgeons who have implanted the cervical or lumbar AxioMed Freedom discs all share their amazement at how simple the discs are to implant and how well the patients do. I expect this experience will result in a revolutionary change in spinal care from fusions to viscoelastic discs.”

Dr. Kingsley R. Chin is a Bohlman trained and board certified orthopedic spine surgeon who practices at the LESS Institute in Florida.

To view the latest cervical and lumbar AxioMed cases done in the past two weeks, visit AxioMed on YouTube.

About AxioMed 
Founded in 2001, AxioMed began its journey of exhaustively proving the Freedom® disc through clinical studies in the U.S. and Europe, research, development and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom disc technology.

Conventus Orthopaedics Appoints Richard Mott to its Board of Directors

MINNEAPOLISSept. 27, 2017 /PRNewswire/ — Conventus Orthopaedics, a medical device company revolutionizing fracture repair surgery, today announced that Richard Mott has been appointed to its Board of Directors, effective immediately.

Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm, where he provides strategic counsel to operating teams for several privately held medical technology and biotech entities in various stages of development.   He is the current Chairman of Silk Road Medical, Relievant MedSystems and 480 Biomedical.  Previously, Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc in late 2007. Prior to Kyphon, Mr. Mott held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as Chief Operating Officer, as well as executive operating roles within the Bristol-Myers Squibb Company.

“We are pleased to welcome Rich to our Board and look forward to benefiting from his extensive track record of success and leadership in the orthopaedic industry,” said Matthew Jewett, President and Chief Executive Officer of Conventus.  “His experience in building and scaling high potential medical device platforms will be invaluable as we continue to introduce additional innovative Cage technology solutions and build a solid foundation for future commercial growth.”

“I am excited to join an organization dedicated to revolutionizing fracture repair surgery and improving outcomes for patients,” said Richard Mott. “It is an especially exciting time to be a part of Conventus as the company prepares to launch an enhanced proximal humerus (PH) system and as compelling data on 125 proximal humerus patients will be presented at the Orthopaedic Trauma Association (OTA) conference in Vancouver next month.”

About Conventus Orthopaedics, Inc.
Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a 3-dimensional platform technology with less invasive solutions to a broad range of challenging periarticular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions to fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients’ return to normal activities.

 

SOURCE Conventus Orthopaedics, Inc.

Orthobiologics Market Worth 6.06 Billion USD by 2022

PUNE, IndiaSeptember 27, 2017 /PRNewswire/ —

According to a new market research report Orthobiologics Market by Product (Viscosupplementation, Synthetic Orthobiologics, DBM, BMP, PRP, BMAC, Allograft), Application (Fracture Recovery, Osteoarthritis, Spinal Fusion, Soft Tissue), End User (Hospitals, ASCs, Academia) – Global Forecast to 2022, published by MarketsandMarkets™, the market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period.

Browse 60 Market Data Tables and 38 Figures spread through 159 Pages and in-depth TOC on “Orthobiologics Market

http://www.marketsandmarkets.com/Market-Reports/orthobiologics-market-162747970.html
Early buyers will receive 10% customization on this report

The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the Orthobiologics Market in North AmericaEuropeAsia Pacific, and the Rest of the World (RoW). Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the Orthobiologics Market. However, high cost pertaining to orthobiologics based treatment is the major factor restraining the market growth to a certain extent.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=162747970

Based on product, the viscosupplementation products segment is estimated account for the largest segment of the market in 2017

On the basis of product, the Orthobiologics Market is segmented into allografts, synthetic orthobiologics, plasma-rich protein (PRP), bone marrow aspirate concentrate (BMAC), demineralized bone matrices (DBM), bone morphogenic protein (BMP), and viscosupplementation products. The viscosupplementation products segment is expected to account for largest share of the Orthobiologics Market in 2017. The large share of this segment can be attributed to the increasing incidence of osteoarthritis of the knee and hip joints among the baby boomer population and lower cost of viscosupplementations.

Based on application, the osteoarthritis and degenerative arthritis segment expected to account for the largest share of the market in 2017

Based on application, the Orthobiologics Market is segmented into fracture recovery, osteoarthritis & degenerative arthritis, spinal fusion, soft tissue injuries, and maxillofacial & dental applications. The osteoarthritis and degenerative arthritis segment is estimated to command the largest share of the global Orthobiologics Market in 2017. The large share of this segment is mainly due to factors such as the significant rise in target patient population across major markets, rising public awareness related to clinical side effects associated with oral medications for pain management, clinical advancements in OA management methodologies, robust healthcare infrastructure & facilities for specific joint replacement surgeries across major markets, and growing clinical evidence validating the efficacy of biologics in OA treatment.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=162747970

In 2017, North America is expected to account for the largest share of the Orthobiologics Market

Geographically, the Orthobiologics Market is segmented into North AmericaEuropeAsia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global Orthobiologics Market in 2017. The growth of this region is attributed to rising incidence of orthopedic and spinal disorders; increasing geriatric population coupled with obesity; growing population exposure to key risk factors; rising number of spinal fusion surgeries and rising patient preference for minimally invasive orthopedic therapies over invasive grafting procedures; and growing physician and patient awareness about the newly introduced treatment procedures and technologies.

The major players in the market are DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, Bioventus, NuVasive, SeaSpine, Arthrex, and Xtant Medical.

Browse Related Reports:

Bone Growth Stimulator Market by Product (Device, Bone Morphogenetic Protein, PRP), Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial), End User (Hospitals, Home Care, Academia, CROs) – Global Forecasts to 2022

http://www.marketsandmarkets.com/Market-Reports/bone-growth-stimulator-market-82341383.html

Spine Biologics Market by Product Type (Bone Graft, Bone Graft Substitute, Platelet Rich Plasma, BMAC), Surgery Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography-Global Forecast to 2020

http://www.marketsandmarkets.com/Market-Reports/spine-biologics-market-67680943.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit Our Blog@ http://mnmblog.org/market-research/healthcare/medical-devices

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets

Medicrea Financial Calendar Amendment

September 27, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, will announce its 2017 Half-Year Results on Monday, 2 October, after market.

On the following day, Tuesday, 3 October, Medicrea will participate in a meeting organized by SFAF (French Society of Financial Analysts) to present the Company’s strategy and results.

The upcoming dates announced on the original schedule remain otherwise unchanged:

• 2017 Third Quarter sales

October 12, 2017*

 2017 Annual sales

January 11, 2018*

*Subject to modification. After market.

Next publication: 2017 Half-Year Results on 2 October, after market.

About Medicrea (www.Medicrea.com)

Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 100,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

For further information, please visit: Medicrea.com.

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED

Contacts

Medicrea
Denys Sournac
Founder, Chairman and CEO
dsournac@Medicrea.com
or
Fabrice Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@Medicrea.com

Wenzel Spine Announces Refinements and Extended Size Range of the VariLift®-C

AUSTIN, TX September 26, 2017 – Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced the commercial availability of the revised VariLift®-C System throughout the U.S.

VariLift-C is now available in three heights, 8mm 9mm and 10mm, allowing surgeons to implant an optimally sized device in a broader patient population. Instrumentation has been modified to reduce size and to improve usability and ergonomics.

“The new features of the VariLift-C system enhances ease of use, and reduces overall exposure and instrumentation footprint. My patients have experienced excellent symptom relief and very low complication rates.  In nearly all cases, VariLift-C procedures are done as outpatient surgeries, with patients returning home same day.” said Dr. Benjamin Gelber, M.D., Chairman, Division of Neurosurgery, Bryan LGH Medical Center in Lincoln, NB and Clinical Associate Professor, Department of Neurosurgery, University of Nebraska College of Medicine.  He further added “Another benefit is no separate bone graft harvest or extenders are necessary for the VariLift-C. procedure. These enhanced features contribute to a very high success rate for my patients.”

VariLift-C is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level. VariLift-C is used to facilitate intervertebral body fusion in the cervical spine and is placed in a unilateral or a bilateral fashion via an anterior approach at the C3 to C7 disc levels using autograft bone.

VariLift-C may be used with or without supplemental fixation.

Wenzel Spine’s Cervical VariLift® Stand-Alone Expandable Interbody Fusion System and the redesigned instruments are now commercially available in the U.S.

About Wenzel Spine, Inc.

Wenzel Spine, Inc. is a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders.  Headquartered in Austin, TX, Wenzel Spine is focused on delivering surgical solutions that improve the overall quality of spine care by simplifying procedures and reducing recovery time. Wenzel Spine seeks to improve patient quality of life by designing and producing devices of the highest quality to support our surgeon clients in the care and treatment of their patients. For more information about the company and our products, visit www.wenzelspine.com.

 

Follow Wenzel Spine on LinkedIn:  https://www.linkedin.com/company/wenzel-spine
Follow Wenzel Spine on Twitter: https://twitter.com/WenzelSpine
Follow Wenzel Spine on Facebook: https://facebook.com/WenzelSpine
Follow Wenzel Spine on Instagram: https://Instagram.com/wenzelspine

For further information, contact:
Chad Neely, Chief Executive Officer
(512) 469-0600

Flower adds to its market leading Ready-For-Surgery™ product line

HORSHAM, Pa.Sept. 25, 2017 /PRNewswire/ — Flower Orthopedics, the leader in Ready-for-Surgery™ extremity implant systems, announces multiple expansions to its product line.  “With these latest additions to our portfolio, we continue our commitment to establish the most comprehensive offering of sterile, surgical, efficiency-based products, producing cost savings for our partners,” said Oliver Burckhardt, President and CEO of Flower Orthopedics.

The Flower Efficiency (E-Kit™) Advanced, a multi-functional, sterile, Ready-for-Surgery™ instrument kit contains all the instruments necessary for an implant procedure. The enhanced E-Kits feature instruments designed to reduce surgical steps and facilitate faster surgery. “The new E-Kits expand upon our sterile Ready-for-Surgery™ instrument platform. The E-Kit can be used for Flower’s plating system, as well as, for both our Cannulated headed and Headless Compression Screw systems. It eliminates the hassle of onsite sterilization. A single sterile E-Kit replaces the instruments in two sterilization trays which undergo costly, timely and sometimes ineffective sterilization cycles,” Burckhardt said.

Developed to provide exceptional anatomic fit and to reduce operating room time, FlowerGraft™ is a comprehensive foot reconstruction platform for Evans and Cotton procedures. FlowerGraft™ is the world’s first system containing pre-shaped, bi-cortical allografts packaged in saline, which can be employed with the specifically designed sterile single-use FlowerGraft™ instrument kit.  According to Elizabeth Hewitt, DPM in Columbus, OH, “With the grafts packaged in saline and the novel single-use instruments, the FlowerGraft™ System saves me up to 30 minutes of OR time. The low profile plates provide anatomic fixation without affecting the adjacent soft tissues.”

Flower Orthopedics also announces the addition of its Headless Compression Screws to complete its comprehensive Ready-for-Surgery™ cannulated screw platform. The Headless Compression Screws are available across several diameters to accommodate the most common foot, ankle, hand and wrist procedures.  Following the principle of driving standardization and surgical efficiency, the Flower Headless Compression screws are used in combination with the Flower E-Kit.

About Flower: Flower Orthopedics was founded in 2012 to drive surgical efficiencies that translate into cost savings. Flower’s development team works tirelessly with leading surgeons focusing on creating advanced implant platforms that are always Ready-for-SurgeryTM.

SOURCE Flower Orthopedics

SeaSpine Announces Launch of Shoreline® Anterior Cervical Standalone System

CARLSBAD, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Shoreline Anterior Cervical Standalone (ACS) System, featuring TruProfile technology.

The Shoreline ACS System is designed to deliver maximum flexibility and modularity, offering zero- and low-profile plating options, including two, three and four hole variations, as well as 10 and 15 degree lordotic implants.  This selection provides surgeons the ability to intraoperatively address a wide range of anatomy, surgical situations or bone.  In addition, TruProfile technology offers a low profile plate design at 1.6mm thickness, minimizing the profile on the anterior aspect of the spine and minimizing cephalad caudal encroachment of adjacent segments.

“Shoreline with TruProfile has met the challenge of combining ease of implant placement and plate fixation to allow for a more responsive approach to specific patient requirements,” stated Dr. James Bruffey, an orthopedic surgeon in San Diego, CA.

All Shoreline interbody implants feature proprietary NanoMetalene surface technology designed to provide a bone-friendly titanium surface while retaining the benefits associated with traditional PEEK devices, such as biocompatibility, a modulus of elasticity like bone, and excellent radiographic visibility for post-operative imaging. NanoMetalene describes a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a proprietary, high-energy, low-temperature process.  Unlike other titanium coating applications, this process maximizes the implant surface area that has titanium nanotopography.

“The modular design of Shoreline with TruProfile is intended to optimize operating room efficiency and maximize procedural flexibility, while NanoMetalene provides the latest in surface technology,” stated Keith Valentine, President and Chief Executive Officer of SeaSpine.  “In addition, we believe the hyperlordotic and large footprint offerings enable surgeons to assemble the best construct option to match patient anatomy.”

About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implant portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implant product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements may include, but are not limited to, statements relating to: the design and other benefits of the Shoreline ACS System, TruProfile technology, and NanoMetalene; the ability of the Shoreline ACS System to optimize operating room efficiency, maximize procedural flexibility, or enable surgeons to assemble the best construct option.  Among the factors that could cause or contribute to material differences between our actual results and the expectations indicated by our forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the clinical needs of surgeons and patients; the limited clinical experience supporting the commercial launch of new products and the risk that such products may require substantial additional development activities, which could introduce unexpected expense and delay; the lack of long-term clinical data supporting the safety and efficacy of the Company’s products; and other risks and uncertainties more fully described in our news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Investor Relations Contact
Lynn Pieper
(415) 309-5999
ir@seaspine.com

Primary Logo

SeaSpine Holdings Corporation

Paragon 28® Increases Its Robust Ankle Fracture Offering – Gorilla® Ankle Fracture Plating System – Posterior Plating System Launched

ENGLEWOOD, Colo.Sept. 26, 2017 /PRNewswire/ — Since its inception, Paragon 28 has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28 has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach and facilitate reproducible results that benefit both the surgeon and patient.

The addition of Posterior Plates to the Gorilla® Ankle Fracture Plating System further expands Paragon 28’s robust foot and ankle specific portfolio.  The Gorilla® Ankle Fracture Plating System now offers surgeons 44 total plates in seven families to address distal fractures of the fibula and tibia.  The Posterior Plates are offered across four families and provide surgeons 20 unique options to address fractures of the tibia and fibula from a posterior approach.

Paragon 28 Gorilla® Ankle Plating System – Posterior Plates

Posterolateral Fibula Plate

  • Narrower in design than the anatomic and straight fibular plates to allow for better fit when placed on the posterior and posterolateral surfaces of the fibula
  • Distal screw configuration is oriented to avoid anatomic structures when used with a lateral or posterior incision
  • Can also be used as an anti-glide plate in order to buttress the distal fragment from shifting proximally

Posterolateral Tibia Plate

  • Contoured to match the anatomy of the posterior tibia
  • The two most distal screw holes are angled superiorly to avoid the concave surface of the tibia
  • Lateral plate placement helps avoid Flexor Hallucis Longus (FHL) tendon

Posteromedial Tibia Plate

  • Designed for a posterior pilon variant fracture
  • Contoured to match the anatomy of the posterior tibia

Trimalleolar Fracture Plate

  • Designed for the posterior malleolar fracture of a trimalleolar fracture
  • Plate has a slight concavity to minimize the need for interoperative bending to match the posterior tibia
  • Plate is designed to prevent superior translation of the fracture fragment, as an anti-glide concept

Paragon 28 is grateful for the significant contributions Dr. Christopher Zingas, MD, Dr. John Kwon, MD and Dr. Michael Houghton, MD made as the surgeon designers of this system.

Product Page:
http://www.paragon28.com/products/ankle-fracture-plating-system/

CONTACT: Jim Edson, Director of Product Management and Marketing, jedson@paragon28.com

 

SOURCE Paragon 28

1st Private Payor Positive Coverage Policy For A Novel & Proven Treatment For Lumbar Spinal Stenosis

NEW YORKSept. 26, 2017 /PRNewswire/ — Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis, announces issuance of a Blue Cross Blue Shield of Michigan Medical Policy, entitled “Interspinous/Interlaminar Stabilization/Distraction Devices (Spacers)” dated September 1, 2017.  The coverage policy may be found here https://www.bcbsm.com/mprApp/MedicalPolicyDocument?fileId=2112720.

Lumbar spinal stenosis (“LSS”), affecting 1.6 million patients annually, is a debilitating and degenerative disease in older patients (>50 yrs) often associated with significant leg and back pain, leg numbness and weakness, causing a significant reduction in an active lifestyle.  Traditional surgical treatment options for LSS includes a decompression that removes bone and soft tissue and may also require a fusion to stabilize the spine.  The coflex® device is a non-fusion, motion preserving stabilization implant, that is FDA PMA approved for the treatment of Lumbar Spinal Stenosis, and can be used in conjunction with a decompression or used in lieu of a spinal fusion.

To learn more about coflex® Interlaminar Stabilization®, please visit www.coflexsolution.com.

Matthew Songer MD, MBA, Assistant Professor College of Human Medicine, Michigan State University – “Over the last four years, I’ve treated 80 patients with coflex®.  In comparison to fusion, coflex® is less-invasive, requires a short hospital stay, allows for a much quicker recovery with return-to-work time in as little as two weeks.  In comparison to decompression-alone, coflex® adds durability to already good outcomes, while maintaining the fast recovery.  I’m delighted insurance coverage will now be available to more of my patients.”

Marc Viscogliosi, Chairman & CEO – “With over 85 peer-review published articles, including landmark 5 year follow-up studies, medical society guidelines, and now with commercial insurance coverage, it is wonderful to be able to expand patient access to the coflex® technology.”

About Paradigm Spine, LLC
Paradigm Spine, LLC was founded in 2004 and remains focused on the design and development of solutions for the disease management of spinal stenosis.  The Company’s signature product is the coflex® Interlaminar Stabilization®device, which has more than 20 years of clinical history and patients treated in more than 40 countries worldwide.

 

SOURCE Paradigm Spine, LLC

PRNewsfoto/Paradigm Spine, LLC)…

Implanet Strengthens JAZZ Intellectual Property Portfolio

September 26, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that the US Patent and Trademark Office (USPTO) has granted two new patents for the JAZZ™ platform.

These two new patents further strengthen the portfolio of 22 patents covering all the aspects of the JAZZ™ platform. It is the result of an extremely proactive and rigorous policy that is one of the strategic keys to commercial development and value creation.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “These two new U.S. patents expand our protection on this highly competitive market. Intellectual Property is essential to Implanet’s formula, we meticulously manage our portfolio. Clinical results support the fact that we possess the band market’s most advanced implants and instrumentation. We will continue to expand the scope of protection covering our JAZZ™ platform and future innovations.

Ludovic Lastennet, CEO of Implanet, adds: “Obtaining these patents is an integral part of our value-creation strategy, we aim to put solid barriers in place in an addressable spine market estimated at $2.1 billion. The systematic growth of our IP protection enables us to reinforce our current commercial partnerships and look towards future strategic alliances.

Next financial press release: revenue for the 3rd quarter of 2017, on October 10, 2017, before market opens.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ™ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ™ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Euronext™ Growth market in Paris.

Disclaimer

This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba
Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen
Tel.: +1 917 385 21 60
implanet@alphabronze.net